Month: 2025-04

香港, 2025年4月22日 - (亞太商訊 via SeaPRwire.com) - 近年來，隨著核藥頂層設計出台及配套支持政策陸續落地，國內核醫藥產業迎來黃金髮展期。據BCC Research數據分析，全球核醫藥市場將從2023年126億美元增長到2029年底的210億美元，在2024年至2029年的預測期內的復合年增長率(CAGR)為8.29%。而專注於放射治療和核醫學的市場情報機構Medraysintell則預期2030年全球核藥市場將達約300億美元。作為國內核藥龍頭，中國同輻（01763.HK）近日披露了截至12月31日止的2024年度報告，中國同輻在2024年實現了營收、淨利的顯著增長，在業績層面交上了令人滿意的答卷，在核藥研發方面也展現出强大的技術轉化能力。業績逐年提升 核醫療裝備成新引擎從財務數據來看中國同輻在2024年實現營業收入人民幣75.75億元，同比增長14.2%；淨利潤8.80億元，同比增長13.3%。從分部業務來看，各領域全面開花。核藥業務作為公司的核心支柱，實現收入41.68億元，佔據總營收的55%。其中，顯像診斷及治療用放射性藥物收入同比增長4.1%，醫藥中心全國佈局成效顯著，鍀標藥物收入同比增長8.7%。呼氣檢測業務持續保持穩定的高市場佔有率，實現收入23.50億元，同比增長1.1%。值得注意的是，2024年中國同輻加速推進高端放療設備國産化，核醫療裝備及相關服務成為增長新引擎，營收達到12.23億元，同比增長31.0%。全新一代Precision放射治療計劃系統成功獲批醫療器械注册證，全球首台螺旋斷層放療系統Tomo C運至山東省腫瘤醫院裝機並入選2024年兩部委（工業和信息化部╱國家衛生健康委）高端醫療裝備推廣應用項目和《天津市首台（套）重大技術裝備推廣應用指導目錄》（2024版），年銷售持續領跑國內市場。放射源產品業務同樣表現出色，實現收入7.16億元，同比增長22.2%。伽瑪刀源、探傷源持續保持穩定的高市場佔有率，中核秦同順利取得甲級輻射安全許可證，鈷-60放射源生產線交付產品200萬居里。40年核技術深耕 構築全產業鏈護城河作為中核集團核技術應用產業發展主體，中國同輻深耕行業逾40年，更通過「6+N」產業佈局形成了核素、核藥、核醫療裝備、核醫學整體解决方案、放射源及應用、輻照應用等核心業務協同發展的生態體系。報告期內，公司新獲專利授權224項，累計有效專利達969項，研發投入强度持續保持行業領先。在核藥研發領域，中國同輻展現出强大的技術轉化能力。氟[18F]化鈉注射液的獲批上市填補了國內骨顯像PET診斷顯像劑市場空白；碘[131I]-MIBG注射液III期臨床收尾，該藥物上市後將為嗜鉻細胞瘤和神經母細胞瘤等神經內分泌腫瘤提供新的診斷方式。值得關注的是，公司前瞻性佈局診療一體化藥物，鑥[177Lu]氧奧曲肽注射液研發進展順利，標志著從單純診斷向精准診療的戰略升級。除了穩住核藥的基本盤外，公司對於核醫療裝備的重視程度逐漸提升。從近年銷售數據來看，核醫療裝備收入穩步上升。2024年全新一代伽馬刀獲批，融合CBCT圖像引導、六維床校正等智能技術，治療效率提升30%。在甲類大型醫用設備市場，中國同輻通過控股子公司中核安科銳佔據絕對主導地位，今年2月，國家衛健委發佈的2024年第二輪甲類大型醫用設備准予許可名單中28台高端放療設備有19台來自該公司，市場佔有率達68%。值得注意的是，公司在鈷60立體定向治療系統等領域的突破，也推動著放療設備國産化替代進程。面對核藥市場的爆發式增長，中國同輻加速醫藥中心全國網絡佈局持續拓展。2024年，新增蘭州正電子藥物生產線，累計投産23條；新增福州鍀藥生產線，累計投産27條。中國同輻建成國內首條萬居裏級鑥[177Lu]生產線及千條級鍺鎵[68Ge-68Ga]發生器産線，實現高端核素國産化突破。值得關注的是，中國同輻通過「母子協同」模式，打造了層次分明的創新生態。2024年，其子公司中核海得威（呼氣檢測）、中核高通（核素）企業獲評國家級專精特新「小巨人」，至此中國同輻旗下專精特新企業總數達18家。其中，中核海得威以「藥盒+儀器」一體化方案佔據呼氣檢測市場主導地位，中核高通則通過「核素-藥物-裝備」全鏈條佈局，成為核技術應用領域標杆。這種「航母戰鬥群」式的創新體系，為公司長期增長提供了可持續動力。全球化佈局拓展發展空間作為中核集團面向人民生命健康科技進軍的主力和先進核科技成果轉化的主通道，中國同輻響應集團「整體・協同」的國際化戰略以及國家「一帶一路」倡議，大力推進國際化戰略，不斷拓展海外市場。2024年實現出口收入達6.27億元，產品遠銷巴西、秘魯、尼日利亞等數十個國家和地區。今年初更是成功簽署孟加拉百萬居裏設計裝源量輻照站設備供應合同，這是繼2024年中標孟加拉核農業研究院設計裝源量百萬居裏伽馬輻照站項目後，又一輻照站設備供應項目落地。該輻照站建成啓用後主要服務於孟加拉醫療領域產品的輻照滅菌，將顯著提升當地醫療產品質量水平及生産加工能力，助力孟加拉醫療產業發展，造福當地民生。在尼日利亞，公司成功簽約核醫療設備整體供應項目，實現集團核醫療裝備整體供應項目首次成功落地。此外，公司還積極拓展東盟市場，放藥配套冷藥成功出口泰國；亦與巴西多個主體簽署戰略合作協議，支撑國家原子能機構與巴西簽署核技術應用領域戰略合作備忘錄。結語在政策支持與市場需求持續釋放的背景下，中國同輻表示將圍繞「健康中國」戰略框架,聚焦「國之所需」，進一步深化核醫藥與高端裝備的協同發展。據其2025年規劃，秦山同位素基地、夾江放射源基地一期及華北醫藥基地一期等重點項目將按節點推進，涉及核素生產、放射源製造及醫藥供應鏈佈局。同時，中國同輻將通過智慧核醫學項目迭代，提升數字化診療服務能力，計劃年內上線不少於3個智能系統。國際化層面，中國同輻將延續「一帶一路」沿線市場拓展策略，依托現有輻照站設備出口、核醫療裝備整體解决方案輸出等業務模式，重點聚焦南美、東南亞、中東、北非等區域市場的合作，未來或通過本地化合作進一步提升全球市場滲透率。公司管理層表示，2025年中國同輻將持續加强科技創新，健全現代產業體系，加快培育發展新質生産力，不斷增强核心功能，提升核心競爭力，加快建成國際知名的同位素與輻射技術應用產品和服務供應集團。 Copyright 2025 亞太商訊 via SeaPRwire.com.

Luxembourg, Apr 21, 2025 - (ACN Newswire via SeaPRwire.com) - Moolec Science SA (NASDAQ:MLEC) ("The Company" or "Moolec"), a science-based food ingredient company focused on producing animal proteins and nutritional oils in plants, today announced that it has entered into a Business Combination Agreement (the "BCA") with Bioceres Group Limited ("Bioceres Group") and other related entities in an all-stock transaction (the "Business Combination"). Subject to the terms and conditions of the BCA, which was signed on April 17, 2025, several parties will transfer their respective holdings in Bioceres Group, Nutrecon LLC ("Nutrecon"), and Gentle Technologies Corp ("Gentle Tech", and together with Bioceres Group and Nutrecon, the "Contributed Entities"), resulting in an enlarged corporate structure with Moolec as the parent company. In exchange, Moolec will issue a combination of up to 87 million newly issued shares and 5 million warrants to the shareholders of the Contributed Entities, as more fully described below in the Timing and Approvals section.Federico Trucco, Bioceres Group's board member and CEO of Bioceres Crop Solutions Corp commented: "The need to accelerate agricultural innovation to address current and future challenges, such as enhancing on-farm profitability and reducing environmental impact, is increasingly evident. Molecular farming, as exemplified by Moolec Science, offers a compelling solution to the challenge of balancing productivity and sustainability. For instance, what soybean yield technology can rival the direct production of 300kg of animal protein from a 3-ton-per-hectare crop?" He then finished: "Moolec's recent transformational transaction represents the kind of bold action needed to drive radical change in agriculture. Integrating technologies and capabilities, along with a holistic perspective on agricultural evolution, are essential for moving beyond incremental improvements. Scale and visibility, both of which are key aspects of this transaction, are crucial to achieving this goal. Bioceres is enthusiastic to be part of a larger, more ambitious Moolec, one that expands its focus from science in food ingredients to a comprehensive ‘cradle-to-cradle' approach."Juan Sartori, Founder and Chairman of Union Group remarked: "This is not just a strategic alignment of businesses, it's the creation of a new kind of company for the 21st century. By combining science, scale, and sustainability, Moolec is positioned to lead a global transformation in how we produce food, materials, and energy. I'm proud to support this vision and the exceptional teams bringing it to life."Following the closing of the Business Combination, Moolec will become uniquely positioned in the agricultural value-chain, with a powerful and validated technology discovery and development engine that can address in a cost-competitive way multiple upstream and downstream needs. Moolec's new value proposition will be centered around modifying or improving seeds and microbes to positively impact the way we utilize land and water resources, while preserving and/or improving human health.Alejandro Antalich, Chairman of Synbio Powerlabs® added: "This combination marks a defining moment for the bioeconomy. By integrating next-gen ingredients, biological ag solutions, and deep-tech manufacturing capabilities under one roof, we are building a company with unmatched scientific depth and commercial reach. Together, we aim to accelerate the shift toward a more sustainable and resilient food system, one that works in harmony with nature, rather than against it."As stated in their most recent annual reports, the companies and brands, which will be controlled or co-controlled by Moolec at the closing of the Business Combination, manage a portfolio of more than 800 patents (or patent applications) and over 550 product registrations, which translates into more than half a billion dollars of goods and services sold in their last fiscal year, to customers in more than 50 different countries.José López Lecube, CFO and Director of Moolec commented: "This transformative transaction marks a new stage for Moolec, positioning the company for growth within a broader organization that facilitates synergies on multiple levels. Becoming part of a larger organization will enable cost efficiencies and significant revenue increase as well as product portfolio diversification. It will also enlarge our investor base, providing the company with new stakeholders who support Moolec's new and more diversified business."Finally, as reported Mr. Gastón Paladini will step down as Chief Executive Officer (CEO), Director and Chairman of the Board, effective immediately following Moolec's Extraordinary General Meeting ("EGM") to be held on April 22, 2025.Key highlights:Ingredient Innovation: Moolec will continue to develop its flagship molecular farming products such as Piggy Sooy™ and GLASO™, while integrating Mycofood™ under the Eternal® brand from Nutrecon.Biological Ag Expansion: Through Bioceres Group, Moolec will now offer upstream technologies for regenerative agriculture, including biological inputs and climate-resilient seeds like Rizobacter®, ProFarm®, and the HB4® trait.Advanced R&D and Services: Leveraging expanded infrastructure, Moolec will offer R&D, CDMO, and regulatory services under the Agrality® and Synbio Powerlabs® brands, which are controlled or co-controlled by Bioceres Group and Nutrecon, respectively.Emerging Tech & Equipment: The Company will also expand its reach into emerging technologies for grain and biomass transformation, especially in the biomaterials space, as well as new concepts on farm equipment, integrating material science, electric mobility, and autonomy. These emerging opportunities are being pursued by Gentle Tech and Bioceres Group subsidiaries.Operational Synergies: The Business Combination is expected to result in significant cost synergies and an integrated management structure, which will be presented at or prior to closing of the Business Combination.Timing and ApprovalsThe Business Combination was unanimously approved by the Board of Directors of all the entities participating in the deal. It is expected to close during the second quarter of 2025 or thereafter, and it is subject to finalizing Moolec's reverse stock split process and re-domicile to the Cayman Islands among other customary closing conditions and regulatory approvals. This includes the approval by Moolec's shareholders at a special meeting of shareholders of proposals relating to the Business Combination. Given that the transaction was originally proposed by about 70% of Moolec's current shareholders, the Company expects strong shareholder support for the Business Combination approval.The Business Combination will be consummated through an equity exchange. Bioceres Group's shareholders will surrender their share ownership in Bioceres Group and will receive in exchange up to 80,590,280 shares of Moolec. The shareholders of 100% of Nutrecon and 50% of Gentle Tech will surrender their ownership in these two entities and will receive in exchange 6,475,000 shares of Moolec and 5,000,000 warrants of Moolec at a strike price of $2.00 per warrant, subject to adjustment based on the results of the reverse stock split process.The intrinsic value of the exchange ratio and the $2 strike price of warrants represent both a compelling premium to Moolec's current stock price, and a unique opportunity to assemble one of the most formidable public companies in the agricultural industry.Description of Contributed Entities and AssetsThe Contributed Entities consist of Bioceres Group and its subsidiaries, Nutrecon and its subsidiaries and Gentle Tech and its subsidiaries.Bioceres GroupBioceres Crop Solutions Corp. (NASDAQ: BIOX)Fully integrated provider of crop productivity solutions, including patented technologies for seeds and microbial agricultural inputs, as well as next generation crop nutrition and protection solutions. The company developed HB4® technology, which confers tolerance to climate changes in soybeans and wheat by allowing these crops to tolerate drought and soil salinity conditions. It also owns and licenses more than 570 products with approximately 750 patents and patent applications in the United States, Canada, Brazil, Argentina and other countries.Bioceres Tech Services (Agrality® & Inmet)Agrality® is a global agricultural services provider catering to agro-industrial companies worldwide. Their comprehensive service offerings encompass seed manufacturing and R&D, field-testing, and regulatory capabilities, ensuring their clients receive end-to-end solutions. Agrality's key assets include advanced seed production facilities, enabling high-quality seed development and production.Inmet specializes in the bio-transformation of agro-industrial residues, offering sustainable solutions for waste management in the agricultural sector. They utilize innovative technologies to convert agricultural waste into valuable products. Additionally, Inmet is involved in the production and assessment of bioplastics, contributing to the development of eco-friendly alternatives to conventional plastics.Nutrecon (Synbio Powerlabs®)Headquartered in Helsinki, Finland, Synbio Powerlabs® is an innovative early-stage biotechnology company specialized in research, development, and production of sustainable fungi-derived ingredients. With state-of-the-art laboratories and a pilot-to-industrial scale precision fermentation facility, the company operates uniquely as both a Research and Technology Organization ("RTO") and a Contract Development and Manufacturing Organization ("CDMO"). This dual role enables Synbio Powerlabs® to seamlessly bridge the gap between cutting-edge biotechnology research and real-world industrial applications, accelerating the commercialization of novel bio-based products. Its flagship product line, marketed under the Eternal® brand, features a diverse portfolio of high-quality, sustainable ingredients derived from fungi, serving multiple industries and applications.Gentle Tech (G-FAS & Gentle Farming)A frontier tech company developing sustainable, autonomous agricultural equipment. Focused on reducing environmental impact through innovations in materials science, information technologies, and alternative energy to maximize efficiency and minimize the carbon footprint. The business model includes G-FAS (selling ultra-light weight harvesting heads directly to farmers) and Gentle Farming (developing machinery for autonomy and intelligent management).Forward Looking StatementsThis press release contains "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec's business and other risks and uncertainties, including those included under the header "Risk Factors" in Moolec's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC"), as well as Moolec's other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.Contact InformationPress & Media: comms@moolecscience.comInvestor Relations: ir@moolecscience.comSOURCE: Moolec Science SARelated Documents:Moolec Science Enters into Transformational Transaction Expanding Across Multiple Technology Platforms.pdf Copyright 2025 ACN Newswire via SeaPRwire.com.